Vishal Gupta

Vishal Gupta

Auto-generated profile, based on publicly available information

Vishal Gupta

Department of Cardiology, Ascension Borgess Hospital, Western Michigan University, Homer Stryker M.D. School of Medicine, Michigan State University, Kalamazoo, Michigan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
VGVishal Gupta
Vishal Gupta
DKDilip R Karnad
Dilip R Karnad
Tetanus is caused by an exotoxin, tetanospasmin, produced by Clostridium tetani, an anaerobic gram-positive bacillus.Tetanospasmin prevents the release of inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the spinal cord, brainstem motor nuclei, and the brain, producing muscle rigidity and tonic spasms.Trismus (lockjaw), dysphagia, laryngeal spasms, rigidity of limbs and paraspinal muscles, and opisthotonic posture are common.Frequent severe spasms triggered by touch, pain, bright light, or sounds may produce apnea and rhabdomyolysis.Autonomic overactivity occurs in severe tetanus causing labile hypertension, tachycardia, increased secretions, sweating, and urinary retention. Dysautonomia is difficult to manage and is a common cause of mortality; magnesium sulfate infusion is often used.Antibiotics (penicillin or metronidazole) and wound care reduce toxin production and human tetanus immune globulin neutralizes the circulating toxin.Nasogastric tube placement for feeding and medications is needed.Early elective tracheostomy is performed in moderate or severe tetanus to prevent aspiration and laryngeal stridor.Benzodiazepines help reduce rigidity, spasms, and autonomic dysfunction. Large doses of diazepam (0.2–1 mg/kg/h) are administered via nasogastric tube.Neuromuscular blocking agents and mechanical ventilation are used for refractory spasms.Mortality ranges from 5% to 50%.

15 June 2023 in The American Journal of Cardiology
Verified
Journal Article
Closed access
SBSandeep Banga
Sandeep Banga
GAGeorge S. Abela
George S. Abela
FSFrank Saltiel
Frank Saltiel
TFTim Fischell
Tim Fischell
JKJagadeesh K. Kalavakunta
Jagadeesh K. Kalavakunta
VGVishal Gupta
Vishal Gupta

1 June 2020 in Diabetes
Verified
Journal Article
Closed access
VGVishal Gupta
Vishal Gupta
VTVaishali Teli
Vaishali Teli
Aim: study the effect of Sacubitril/valsartan (SV) combination therapy on cardio-renal (CR) biomarkers in T2DM with preserved ejection fraction (pEF); diastolic dysfunction and or LVH on 2D echocardiogram (E) and elevated N-terminal prohormone B-type natriuretic peptide (NT-proBNP) >125. Methodology: between July and Sept 2018, 109 T2DM patients aged 18-75 yrs, irrespective of baseline A1c, receiving SV were identified. Patients were analysed every 2-3months for CR biomarkers (body mass index (BMI), A1c, systolic (S) BP, diastolic (D) BP, Lipid profile (TC, LDL, TG, HDL), Hs-CRP, NT-ProBNP, creatinine, eGFR and microalbumin/creatinine ratio {UACR} and data presented at 1 yr. T2DM with H/O IHD, reduced EF(5.5Meq/L and eGFR<45 were excluded. Baseline characteristics were analyzed using descriptive statistics. Continuous variables were analysed using paired and unpaired t-test expressed as mean ± standard error. For interaction between drug class, ANOVA was used and p value <0.05 was considered significant (S). Results: Baseline characteristics: Male 43%, Female 66%. Avg (age 63.16 ±8.325yrs, BMI 30.45±5.52, A1c% 7.1±1.2, egfr 90.31±30.45, UACR mg/gm 180.07±553.4, hs-CRP mg/dl 2.53±3.41, NT-proBNP 370.07±543.30 Ng/L). 64.2% received canagliflozin, 11.9% liraglutide, 94.5% Metformin, 61.5% gliptins, 65.1% gliclazide, 44% calcium channel blockers and 100% statin (rosuvastatin) Baseline (B) to 1yr: There was S reduction in SBP, DBP, A1c, TC, LDL, HDL, UACR, hs-CRP and NT-ProBNP NT-proBNP: there was S reduction from B to 3 mths (84.26±31.86, p-0.009), 6mth - 12 mths (39.95±17.40,p-0.024) and B-12mths (155.69±744.10,p-0.001). There was no diff seen 3-6mths (38.09±38.03, p-0.320). There was an interaction seen with Liraglutide in terms of NT-proBNP and UACR. Conclusion: SV may be effective in reducing NT-ProBNP in T2DM with pEF Disclosure: V. Gupta: None. V. Teli: None.

1 April 2001 in Gastroenterology
Verified
Journal Article
Closed access
VGVishal Gupta
Vishal Gupta
DSDavid Sheffield
David Sheffield
GVG. Nicholas Verne
G. Nicholas Verne